Abstract
Purpose. The characterization of recombinant MN gp120/alum vaccine requires the study of the gp120-alum interaction for the successful formulation of an alum-based HIV-1 vaccine.
Methods. Several observations suggest that the gpl20-alum interaction is weak, wherein buffer counterions such as phosphate, sulfate, bicarbonate may cause the desorption of gp120 from alum. Comparison of gp120 with other proteins using particle mobility measurements shows that the weak binding of gp120 to alum is not an anomaly. Serum and plasma also cause desorption of gp120 from alum with a half-life of only a few minutes, wherein this half-life may be faster than the in-vivo recruitment of antigen presenting cells to the site of immunization.
Results. Immunization of guinea pigs, rabbits and baboons with gp120 formulated in alum or saline demonstrated that alum provides adjuvant activity for gp120, particularly after early immunizations, but the adjuvant effect is attenuated after several boosts.
Conclusions. These observations indicate that both the antigen and the adjuvant require optimization together.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
G. J. LaRosa, J. P. David, K. Weinhold, J. A. Waterbury, A. T. Profy, J. A. Lewis, A. J. Langlois, G. R. Dreedsman, R. N. Boswell, P. Sheeduck, L. H. Holley, M. Kamplus, D. P. Bolognesi, T. J. Mathews, E. A. Emini and S. D. Putney. Conserved sequences and structural elements in the HIV-1 principal neutralizing determinant. Science, 249:932–935 (1990).
P. W. Berman, T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobba nd J. W. Eichberg. Protection of chimpanzees from infection by HIV-1 after vaccination with gp120 but not gp160. Nature, 345:622–625 (1990).
H. S. Warren and L. A. Chedid. Future prospects for vaccine adjuvants. CRC Crit. Rev. Immunol. 8:83–101 (1988).
H. S. Warren, F. R. Vogel, and L. A. Chedid. Current status of immunological adjuvants. Annu. Rev. Immunol. 4:369–388 (1986).
S. Shirodkar, R. L. Hutchinson, D. L. Perry, J. L. White and S. L. Hem. Aluminum compounds used as adjuvants in vaccines. Pharm. Res., 7:1282–1288 (1990).
J. L. Cleland, C. R. Kensil, A. Lim, N. E. Jacobsen, L. Basa, M. Spellman, D. Bedore and M. F. Powell. Isomerization and Formulation Stability of the Vaccine Adjuvant QS21. (J. Pharm. Sci., in press, 1995).
GENES: J. DiStefano, III, Biocybernetics Laboratory, UCLA, Los Angeles, CA, 1994; ADAPT: D. D'Argenio and A. Schumitzky, Biomedical Simulations Resource, USC, Los Angeles, CA 1992.
P. M. Callahan, A. L. Shorter, S. L. Hem. The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm. Res. 8:851–858 (1991).
E. M. Morefield, G. E. Peck, J. R. Feldkamp, J. L. White and S. L. Hem. Role of water in the aging of aluminum hydroxide suspensions. J. Pharm. Sci., 75:403–406 (1986).
S. L. Nail, J. L. White and S. L. Hem. Structure of aluminum hydroxide Gel II. Aging mechanism. J. Pharm. Sci., 65:1192–1195 (1976).
S. L. Nail, J. W. White and S. L. Hem. IR Studies of development of order in aluminum hydroxide gels. J. Pharm. Sci., 65:231 (1976).
S. J. Seeber, J. L. White and S. L. Hem. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J. Parenter. Sci. Technol., 45:156–159 (1991).
J. Mordenti, T. Nguyen, D. Eastman, G. Osaka, S. Frie, R. P. Weissburg, P. Berman, P. Abramowitz, J. DiStefano, III, and M. F. Powell. unpublished data, 1994.
M. A. Aprile and A. C. Wardlaw. Aluminum compounds as adjuvants for vaccines and toxoids in man: A review. Can. J. Public Health, 57:343–360 (1966).
S. L. Hem and J. L. White. Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. J. Parenteral Sci. Tech., 38:2–10 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weissburg, R.P., Berman, P.W., Cleland, J.L. et al. Characterization of the MN gp120 HIV-1 Vaccine: Antigen Binding to Alum. Pharm Res 12, 1439–1446 (1995). https://doi.org/10.1023/A:1016266916893
Issue Date:
DOI: https://doi.org/10.1023/A:1016266916893